ArticleBMC microbiology2025
Rifaximin resistance in Clostridioides difficile is associated with specific rpoB alleles and multilocus sequence typing (MLST) clades.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The underappreciated role of rifampin in shaping the epidemiology of RT027-like Clostridioides difficile lineages.The Journal of antimicrobial chemotherapy · 2026Article
- Multi-drug resistantFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesRifaximin (RFX) has recently been suggested as an alternative treatment option for Clostridioides difficile infection. This study reports the survey on RFX susceptibility within a C. difficile test cohort that represents the five clinically relevant phylogenetic clades.
methodsAgar dilution assays were conducted to determine the minimum inhibitory concentrations (MICs) of RFX for 129 clinical C. difficile isolates from Germany (86), Indonesia (29), and Ghana (14). Genome sequence data were obtained for 50 representative isolates, including all those with a minimum inhibitory concentration MIC[RFX] of ≥ 32.0 µg/mL, to identify the underlying rpoB gene resistance alleles, determine the multilocus sequence typing (MLST) sequence types (STs), and infer phylogenetic relatedness.
results10.1% of the isolates were found to be resistant to RFX. The resistance rate varies by region, with 4.7% in Germany, 27.6% in Indonesia, and 7.1% in Ghana. Three distinct rpoB alleles were associated with RFX resistance. The presence of a specific rpoB allele correlates with the MLST-based ST of the isolate, indicating that the rifaximin-resistant isolates belong to phylogenetic clades 1, 2, and 4. These isolates are represented by six different ribotypes: 010, 017, 027, 046, 084, and 131. Furthermore, we identified seven amino acid substitutions resulting from SNPs in the rpoB gene through alignment analysis. These substitutions are found in both RFX-resistant and susceptible isolates, suggesting that they are neutral mutations in relation to RFX susceptibility. These observations also indicate that RFX resistance arose independently in different clades.
conclusionsA substantial rate of RFX resistance, particularly among Indonesian isolates, was observed. This may be attributed to the prolonged use of rifampicin, especially in the treatment of tuberculosis. RFX resistance has been linked to specific amino acid substitutions in the β-subunit of RNA polymerase encoded by the rpoB gene. To the best of our knowledge, one of the identified RFX resistance-associated rpoB alleles (H502N, R505K, I750M) has not been previously described, whereupon, the amino acid substitutions I750M as well as I750V, E1037Q, A1205V, N1207A, A1208T, and D1232E were identified as neutral mutations that do not confer resistance to RFX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.